[Malondialdehyde and reduced glutathione increase in patients with chronic stable ischaemic cardiopathy]. / Incremento de las concentraciones séricas de malondialdehído y glutatión reducido en pacientes con cardiopatía isquémica crónica estable.

BACKGROUND AND OBJECTIVE: Cardiovascular diseases are associated with the ischemia/reperfusion phenomena and therefore to the oxidation/antioxidation balance. The aim of this study was to determine malondialdehyde, nitric oxide, glutathione, ascorbic and dehydroascorbic acid in patients with chronic ischemic heart disease. PATIENTS AND METHOD: 32 male patients, with chronic ischemic heart disease, between 40 and 60 years of age were studied. These individuals were divided in two groups: 16 with hypertension and 16 without hypertension. Both groups were compared with 31 healthy male subjects (control group). RESULTS: Significant differences (p < 0.001) was observed in malondialdehyde between no-hypertension ischemic group: 5.3 (1.5) microM and the hypertension ischemic group: 4.8 (1.3) microM in contrast with the healthy group: 2.2 (0.5) microM. Hypertension ischemic group showed significant greater reduced glutation levels: 286.1 (31.4) microg/ml than control group 262.0 (38.8) microg/ml; p < 0.03 and no-hypertension ischemic group: 256.4 (41.5) microg/ml; p < 0.02. No significant difference in the rest of the parameters for all study groups. CONCLUSIONS: Oxidation/antioxidation balance during chronic ischemic heart disease can be considered as a good metabolic ischemia indicator, that used in the monitoring and therapeutic evaluation could detect molecular changes that anticipate installation of tissue damage.

Incremento de las concentraciones séricas de malondialdehído y glutatión reducido en pacientes con cardiopatía isquémica crónica estable / Malondialdehide and reduced glutathione increase in patients with chronic stable ischaemic cardiopathy

FUNDAMENTO Y OBJETIVO: Las enfermedades cardiovasculares están asociadas a isquemia/reperfusión. El objetivo de este estudio fue determinar el malondial de hído,óxido nítrico, glutatión reducido, ácido ascórbico y ácido deshidroascórbico en cardiópatas isquémicos crónicos. PACIENTES Y MÉTODO: Se estudió a 32 varones con cardiopatía isquémica crónica, de entre 40 y 60años, que se dividieron en 2 grupos: uno constituido por 16 sujetos hipertensos y el segundo formado por 16 pacientes sin hipertensión. Ambos grupos se compararon con 31 varones sanos (grupo control).RESULTADOS: El malondial de hído presentó un incremento estadísticamente significativo (p < 0,001) en los pacientes con cardiopatía no hipertensiva (media[desviación estándar] de 5,3 [1,5] µM) y en los que tenían cardiopatía hipertensiva (4,8 [1,3] µM) comparados con los individuos sanos (2,2 [0,5] µM). El grupo de cardiópatas hipertensos presentó un valor de glutatión reducido significativamente mayor(286,1 [31,4] µg/ml) que el de los individuos cardiópatas sin hipertensión: (256,4 [41,5] µg/ml) (p <0,02) y que el grupo control (262,0 [38,8] µg/ml)(p < 0,03). No hubo diferencias significativas en el resto de los parámetros para todos los grupos. CONCLUSIONES: El equilibrio oxidación/antioxidación durante la cardiopatía isquémica crónica puede considerarse como un buen indicador metabólico de isquemia/reperfusión y llegar a detectar los cambios moleculares que anteceden a la instauración de la lesión tisular

BACKGROUND AND OBJECTIVE: Cardiovascular diseasesare associated with the ischemia/reperfusion phenomenaand there fore to the oxidation/antioxidation balance. The aim of this study was to determine malondialhehyde, nitric oxide, glutathione, ascorbic and dehydroascorbic acid in patients with chronic ischemic heart disease. PATIENTS AND METHOD: 32 male patients, with chronicischemic heart disease, between 40 and 60 years of age were studied. These individuals were divided in two groups: 16 with hypertension and 16without hypertension. Both groups were compared with 31 healthy male subjects (control group).RESULTS: Significant differences (p < 0.001) was observed in malondialdehyde between no-hypertension ischemic group: 5.3 (1.5) µM and the hypertension ischemic group: 4.8 (1.3) µM in contrast with the healthy group: 2.2 (0.5) µM. Hypertension ischemic group showed significant greater reduced glutation levels: 286.1 (31.4)µg/ml than control group 262.0 (38.8) µg/ml; p <0.03 and no-hypertension ischemic group: 256.4(41.5) µg/ml; p < 0.02. No significant difference in the rest of the parameters for all study groups. CONCLUSIONS: Oxidation/antioxidation balance during chronic ischemic heart disease can be considered as a good metabolic ischemia indicator, that used in the monitoring and therapeutic evaluation could detect molecular changes that anticipatein stallation of tissue damage